- Home
- FNWD vs ORGO Comparison
FNWD vs ORGO Comparison
Compare FNWD & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNWD | ORGO |
|---|---|---|
| Founded | 1994 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.1M | 127.6M |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FNWD | ORGO |
|---|---|---|
| Price | $43.60 | $0.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 7.7K | ★ 765.7K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | $10.81 | N/A |
| Revenue Next Year | $5.26 | $37.55 |
| P/E Ratio | $43.41 | ★ N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $30.05 | $0.93 |
| 52 Week High | $45.90 | $7.08 |
Technical Indicators
Market Signals| Indicator | FNWD | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 61.46 | 23.69 |
| Support Level | $42.56 | N/A |
| Resistance Level | $44.01 | $2.57 |
| Average True Range (ATR) | 0.83 | 0.08 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 95.15 | 11.21 |
Price Performance
Historical ComparisonAbout FNWD Finward Bancorp
Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.